Delivery Order SPE2DB22D2006-SPE2DB25FW3HV
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,408.90 to AmerisourceBergen Drug Corp for the supply of Bosulif 100 mg tablets (120-count units). This firm fixed-price contract, awarded on August 13, 2025, with an ultimate completion date of September 4, 2025, represents a non-set-aside, competitively awarded procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Bosulif is a prescription oncology...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for BOSULIF 400 mg tablets (30-count) with a ceiling value of $11,815.63. The contract, issued on August 5, 2025, with an ultimate completion date of August 26, 2025, represents a firm fixed-price delivery order under a non-set-aside competitive procurement. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Bosulif 400 mg tablets (30-count units) under a firm fixed price contract with a ceiling value of $11,815.63 and completion deadline of August 29, 2025. This is a non-set-aside, competitively awarded delivery order that represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, a major...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of BOSULIF 400 mg tablets (30-count packages) with a ceiling value of $23,631.26. The contract is a firm fixed-price delivery order with an ultimate completion date of September 2, 2025, and carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $5.7K to AmerisourceBergen Drug Corp for 120 tablets of Bosulif 100 mg, a tyrosine kinase inhibitor used in oncology treatment. The contract was competitively awarded without set-aside provisions under firm fixed pricing terms, with performance at the vendor's Conshohocken, Pennsylvania location and an ultimate completion date of August 15, 2025. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $11,239.34 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply 4562447812 Bosulif 400 MG tablets. The contract has no set-aside designation and requires delivery of 30 tablets to Conshohocken, Pennsylvania by November 1, 2023. As the Defense Logistics Agency is responsible for procuring pharmaceuticals and medical supplies for the U.S. military and other government agencies,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Bosulif 100 mg tablets (120-count units) with a ceiling value of $5,704.45. This firm fixed-price delivery order is scheduled for completion by August 22, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's capability...
- The Defense Logistics Agency awarded a $11,239.34 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the delivery of 4562473623 BOSULIF 400 MG TABLET 30S. The place of performance will be in Conshohocken, Pennsylvania, with all items to be delivered by November 3, 2023. No set-aside designation was used for this procurement. As the Defense Logistics Agency is responsible for worldwide logistics support of the United...
- The Defense Logistics Agency awarded a $11,239 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 4561678892 BOSULIF 400 MG TABLET 30S. This order was placed under an existing Prime Vendor contract vehicle to supply pharmaceutical products to DLA and the Department of Defense. Amerisourcebergen will deliver the Bosulif tablets to a facility in Conshohocken, Pennsylvania by August 23, 2023, fulfilling requirements on behalf of the military's medical supply chain program. No...
- The Defense Logistics Agency (DLA) awarded a $4,991.27 firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply BOSULIF 100 MG TABLET 120S. This award is part of a larger indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a period of performance through December 31, 2025. The IDC is the primary contract vehicle for Amerisourcebergen to deliver pharmaceutical products...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW3HVDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for BOSULIF 100 mg tablets (120-count) valued at $11,408.90 on August 12, 2025, with an ultimate completion date of September 3, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. BOSULIF (bosutinib) is a targeted cancer therapy used in the treatment of chronic myeloid leukemia, reflecting the Defense Logistics Agency's role in procuring specialized pharmaceutical products for military and federal healthcare systems. This delivery order operates under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion comprehensive global pharmaceutical support vehicle running through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical prime vendor for federal medical procurement, supplying an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to support military healthcare programs and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.4k | 8/12/25 |